BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.

CACCAMO, N., MERAVIGLIA, S., CICERO, G., GULOTTA, G., MOSCHELLA, F., CORDOVA, A., et al. (2008). Aminobisphosphonates as New Weapons for gammaDelta T Cell-Based Immunotherapy of Cancer. CURRENT MEDICINAL CHEMISTRY, 15(12), 1147-1153 [10.2174/092986708784310468].

Aminobisphosphonates as New Weapons for gammaDelta T Cell-Based Immunotherapy of Cancer

CACCAMO, Nadia Rosalia;MERAVIGLIA, Serena;CICERO, Giuseppe;GULOTTA, Gaspare;MOSCHELLA, Francesco;CORDOVA, Adriana;GULOTTA, Eliana;SALERNO, Alfredo;DIELI, Francesco
2008-01-01

Abstract

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
2008
CACCAMO, N., MERAVIGLIA, S., CICERO, G., GULOTTA, G., MOSCHELLA, F., CORDOVA, A., et al. (2008). Aminobisphosphonates as New Weapons for gammaDelta T Cell-Based Immunotherapy of Cancer. CURRENT MEDICINAL CHEMISTRY, 15(12), 1147-1153 [10.2174/092986708784310468].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/37794
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 25
social impact